DRG Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations across Asia Pacific (Australia, Hong Kong, Indonesia, Malaysia, New Zealand, Philippines, Singapore, Taiwan, Thailand, and Vietnam). We report both the incidence and prevalence of soft tissue sarcoma for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at the first line of therapy is also forecast across the major mature pharmaceutical markets.

DRG Epidemiology's soft tissue sarcoma forecast will answer the question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of soft tissue sarcoma over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following soft tissue sarcoma subpopulations:

  • Diagnosed incident cases—all sites.
  • Diagnosed incident cases—by specific sites.
  • Diagnosed prevalent STS cases—by extent of disease (metastatic or non-metastatic).
  • First-line drug-treatable cases.
  • … and more (details available on request).

Note: Coverage may vary by country.

Table of contents

  • Asia-Pacific
    • Introduction
      • Key Findings
        • Incidence of Soft Tissue Sarcoma of all sites per 100,000 per Year Among People of All Ages in 2020 and 2030
        • Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Soft Tissue Sarcoma of all sites over the Next 10 Years
    • Epidemiology Data
    • Methods
      • Newly Diagnosed Incidence
      • Stage Distribution
      • Recurrent Incidence
      • Diagnosed Prevalence
      • Drug-Treatable Populations
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Narendra Parihar

Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.


Related Reports

Soft Tissue Sarcoma | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key soft tissue sarcoma patien...

View Details

Soft Tissue Sarcoma | Epidemiology | Epidemiology Dashboard

DRG Epidemiology’s coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence...

View Details

Soft Tissue Sarcoma | Epidemiology | Americas

DRG Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations across the Americas (Argentina, Canada, Chile, Colombia, and Peru). We report...

View Details

Soft Tissue Sarcoma | Epidemiology | Europe

DRG Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations across Europe (Austria, Belgium, Czech Republic, Denmark, Finland, Greece, Ne...

View Details